
Please try another search
(Reuters) - GlaxoSmithKline (NYSE:GSK) and U.S. partner Vir Biotechnology (NASDAQ:VIR) will boost production of their antibody-based COVID-19 treatment by adding a second manufacturing plant to help meet soaring demand in the United States.
The U.S. government last week signed a deal with the drugmakers to buy 600,000 more doses of the therapy, sotrovimab, for an undisclosed sum.
The GSK-Vir therapy has shown more promise against the Omicron variant in lab studies than treatments from major rivals Eli Lilly (NYSE:LLY) and Regeneron (NASDAQ:REGN).
"GSK had been planning to introduce another production facility to our manufacturing network in advance of Omicron," a GSK spokesperson told Reuters on Friday.
"The second site provides GSK additional scale and diversity given the pandemic uncertainty."
Deliveries of the 600,000 additional doses will be carried out through the first quarter of 2022, the spokesperson said.
The Wall Street Journal reported on Friday that GSK and Vir were expected to make the first deliveries in February.
The United States is reporting an average of 752,698 new coronavirus infections a day, according to a Reuters analysis of official data, fuelling the urgent need for effective solutions.
The Biden administration in November signed contracts worth about $1 billion for an unknown number of doses of sotrovimab before the rapid spread of Omicron, and has said it would control the distribution of the drug in the country.
By Davit Kirakosyan Zscaler (NASDAQ:ZS) reported its Q3 results, with EPS of $0.17 coming in better than the Street estimate of $0.11. Revenue grew 63% year-over-year to $286.8...
By Davit Kirakosyan Autodesk (NASDAQ:ADSK) reported its Q1 results, with EPS of $1.43 coming in better than the Street estimate of $1.35. Revenue increased 18% year-over-year to...
By Davit Kirakosyan Ulta Beauty (NASDAQ:ULTA) shares were trading around 8% higher after-hours following the company’s reported Q1 results, with EPS of $6.30 coming in better than...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.